By Frank Prenesti
Date: Monday 01 Oct 2018
(Sharecast News) - AstraZeneca said it had agreed a $200m deal with Germany's Cheplapharm Arzneimittel for the European commercial rights to Atacand and Atacand Plus heart and hypertension treatments.
| Sunday share tips: AstraZeneca, Genus, 'Dogs of ... | 30-Jul-2017 | ShareCast |
| AstraZeneca co-develops treatment for Alzheimer'... | 09-Dec-2016 | ShareCast |
No recent information was found.
| Questor :AstraZeneca | 29-Apr-2014 | Telegraph |
| Questor : AstraZeneca | 24-Jan-2014 | Telegraph |
| Questor:AstraZeneca | 22-Dec-2011 | Telegraph |
| Investment Column:AstraZeneca | 28-Oct-2011 | The Independent |
| Investment Column: AstraZeneca | 23-Jun-2011 | The Independent |
| Currency | UK Pounds |
| Share Price | 12,796.00p |
| Change Today | 3.08p |
| % Change | 2.47 % |
| 52 Week High | 12,994.00 |
| 52 Week Low | 9,642.00 |
| Volume | 837,856 |
| Shares Issued | 1,264.16m |
| Market Cap | £161,762m |
| Strong Buy | 10 |
| Buy | 13 |
| Neutral | 3 |
| Sell | 0 |
| Strong Sell | 1 |
| Total | 27 |

| Time | Volume / Share Price |
| 16:29 | 25 @ 12,796.00p |
| 16:29 | 7 @ 12,794.00p |
| 16:29 | 2 @ 12,794.00p |
| 16:29 | 8 @ 12,794.00p |
| 16:29 | 8 @ 12,794.00p |
You are here: research